Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab.

Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab.

J Crohns Colitis. 2018 May 09;:

Authors: Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M

Abstract
Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess its efficacy in patients with Crohn disease have been published. On the other hand, the drug fact sheet states that secukinumab should be used with caution in patients with inflammatoy bowel disease. Although the drug has shown to worsen these pathologies, there are no published data of cases in which the patient is first diagnosed with inflammatory bowel disease during secukinumab treatment. We present two cases of emergence of inflammatory bowel disease in patients with plaque psoriasis and ankylosing spondylitis treated with secukinumab.

PMID: 29746636 [PubMed – as supplied by publisher]

PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29746636?dopt=Abstract